Paclitaxel liposome alone or combined with carboplatin in the treatment of 36 patients with advanced non-small-cell lung cancer
WANG Bin
HAO Xue-zhi
HU Xing-sheng
ZHANG Xiang-ru
Abstract：Objective:To evaluate the efficacy and toxicity of paclitaxel liposome alone or combined with carboplatin in the treatment of advanced non-small-cell lung cancer. Methods: Paclitaxel liposome (135 ～175 mg· m ~(-2)) alone on day 1, or combined with carbopatin ( AUC = 5 or 350 mg· m~(-2) ) on day 2 of a 21 -day cycle was ad-ministrated to chemotherapy-nafve patients with advanced non-small-cell lung cancer. Results:In 33 evaluable pa-tients, complete response was not observed, partial response rate was 24. 2% (8/33) , no change was 39. 4% ( 13/33 ) , and progress disease was36. 4% ( 12/33 ) . The common adverse effects were neutropenia ( 86. 1 % , 31/ 36) , and no hypersensitiveness occurred. Conclusion: Paclitaxel liposome has similar efficacy as paclitaxel in the treatment of advanced non-small-cell lung cancer. In this therapy, the use of polyethoxylated castor oil, ethanol and large dose cremesone can be avoided, so the incidence of the related adverse events can be lowered.
Keywords：paclitaxel liposomechemotherapynon-small-cell lung cancer
Publication Date：2009-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：4( 1963-1965,1968 )